OSUR · CIK 1116463
What OraSure Technologies, Inc. told the SEC could break it.
OraSure's register is dominated by how quickly a single large customer can vanish: its biggest non-commercial customer, the U.S. government buying InteliSwab COVID-19 tests, fell from 63% of consolidated revenue in 2023 to 24% in 2024 to about 3% in 2025 — a stark illustration of its dependence on a few big customers. That same government reliance carries compliance exposure, subjecting it to the extraordinary provisions of U.S. government contracts (audit, termination for convenience) and to shifts in federal funding and priorities. On the supply side, many raw materials and components for its DNA Genotek products, including the Oragene line, come from sole-source suppliers, so a supplier's acquisition by a competitor or loss could cause delays, higher costs or interruption.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Revenue cliff from a single non-commercial (U.S. government) customerhigh
OraSure's largest non-commercial customer (the U.S. government, via InteliSwab COVID-19 tests) collapsed from 63% of consolidated revenue in 2023 and 24% in 2024 to ~3% in 2025, illustrating extreme dependence on a few large customers that can disappear.
“One non-commercial customer accounted for approximately 3% of the Company's consolidated net revenues for the year ended December 31, 2025 and 24% and 63% for the years ended December 31, 2024 and 2023, respectively.”
SEC filing →As of 2026
Sole-source dependency
- Sole-source suppliers for DNAG (Oragene) raw materials and componentshigh
Many raw materials and components for OraSure's DNA Genotek products, including the Oragene product line, are purchased from sole-source suppliers; if a sole-source supplier were acquired by a competitor or ceased supply, OraSure could face delays, higher costs, or interruption.
“many of the raw materials used in the Company's DNAG products, including its Oragene ® product line, and components used in these products are also purchased from third parties, some of which are purchased from a sole-source supplier.”
SEC filing →As of 2026
Regulatory & policy
- Dependence on and compliance burden of U.S. government contractsmedium
OraSure's government funding and sales subject it to the extraordinary provisions of U.S. government contracts (audit, termination for convenience, compliance), and changes in government funding/priorities can sharply alter its revenue.
“As a result of the Company's U.S. government funding and product sales to the U.S. government, it must comply with laws and regulations relating to the award, administration and performance of U.S. government contracts.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
U.S. Centers for Disease Control and Prevention (CDC)
“the Company was selected to provide its OraQuick ® HIV Self-Tests in support of the CDC "Together Take me Home," HIV self-test program. Under the program, the CDC is expected to provide $41.5 million over a five-year period to support community testing.”
Cited →Biomedical Advanced Research and Development Authority (BARDA)
“an $8.6 million contract with BARDA to develop an updated Ebola test on the OraQuick ® testing platform, which was subsequently modified in September 2023 to add an additional $6.8 in funding to be used to obtain the appropriate regulatory approvals.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch